---
title: "GemPharmatech Co., Ltd. (688046.SH)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/688046.SH.md"
symbol: "688046.SH"
name: "GemPharmatech Co., Ltd."
industry: "Life Sciences Tools and Services"
---

# GemPharmatech Co., Ltd. (688046.SH)

| Item | Detail |
|------|--------|
| Industry | Life Sciences Tools and Services |
| Location | CN Market |
| Website | [www.gempharmatech.com](https://www.gempharmatech.com) |

## Company Profile

GemPharmatech Co., Ltd., a contract research organization, provides genetically engineered mouse models and preclinical research services to the scientific community worldwide. The company offers mouse models, including knockout and conditional knockout mouse, disease mouse, immunodeficient mouse, g...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-16T04:30:09.000Z

**Overall: B (0.39)**

**Industry**: Life Sciences Tools and Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 6 / 27 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 15.49% |  |
| Net Profit YoY | 31.49% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 3.19 |  |
| Dividend Ratio | 0.82% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 6.98B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 793.28M |  |


**Multi Score**: B

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 6.66% | C |
| Profit Margin | 18.20% | A |
| Gross Margin | 100.00% | A |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 15.49% | B |
| Net Profit YoY | 31.49% | B |
| Total Assets YoY | 0.00% | C |
| Net Assets YoY | 3.11% | C |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 549.35% | C |
| OCF YoY | 15.49% | B |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.00 | E |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 0.00% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - GemPharmatech Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "6.66%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "18.20%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "15.49%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "31.49%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "0.00%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "3.11%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "549.35%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "15.49%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "0.00%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | WuXi AppTec (SH.603259) | A | A | C | B | B | B |
| 02 | Pharmaron (SZ.300759) | B | B | C | C | B | B |
| 03 | Chemexpress (SH.688131) | B | A | C | C | B | B |
| 04 | HitGen (SH.688222) | B | B | D | B | B | B |
| 05 | Sepax Technologies (SH.688758) | C | B | E | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 57.43 | 9/27 | 63.24 | 55.47 | 44.52 |
| PB | 3.19 | 10/27 | 3.34 | 3.03 | 2.43 |
| PS (TTM) | 9.27 | 18/27 | 9.88 | 9.16 | 7.50 |
| Dividend Yield | 0.82% | 4/27 | 1.58% | 0.91% | 0.78% |

## Institutional View

### Analyst Rating Distribution

> As of 2025-12-02T16:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 3 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 17.02 |
| Highest Target | 23.00 |
| Lowest Target | 20.89 |

## References

- [Company Overview](https://longbridge.com/en/quote/688046.SH/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/688046.SH/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/688046.SH/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.